Cerence Inc. Prices Offering of $150 Million 3.00% Convertible Senior Notes due 2025
BURLINGTON, Mass., May 29, 2020 (GLOBE NEWSWIRE) — Cerence Inc. (NASDAQ: CRNC), AI for a world in motion, announced today […]
Datadog Announces Pricing of Upsized Offering of $650 Million Convertible Senior Notes
NEW YORK, May 29, 2020 (GLOBE NEWSWIRE) — Datadog, Inc. (Nasdaq: DDOG), the monitoring and analytics platform for developers, IT […]
GRAVITY REPORTS FIRST QUARTER OF 2020 RESULTS AND BUSINESS UPDATES
Seoul, May 29, 2020 (GLOBE NEWSWIRE) — GRAVITY Co., Ltd. (NasdaqGM: GRVY) (“Gravity” or “Company”), a developer and publisher of […]
EHang Reports First Quarter 2020 Unaudited Financial Results
– Solid Results Despite Pandemic Challenges– YoY Growth in Revenue, Gross Margin and Air Mobility Solutions– Global Progress: U.S., Spain, […]
OraSure Technologies Appoints Lelio Marmora to Board of Directors
BETHLEHEM, Pa., May 29, 2020 (GLOBE NEWSWIRE) — OraSure Technologies, Inc. (NASDAQ: OSUR), a leader in point of care diagnostic […]
Jura Energy Corporation Announces Update to Annual and Q1 Filings
CALGARY, Alberta, May 29, 2020 (GLOBE NEWSWIRE) — Jura Energy Corporation (“Jura” or the “Company”) is providing an update on […]
Huize Holding Limited Reports First Quarter 2020 Unaudited Financial Results
SHENZHEN, China, May 29, 2020 (GLOBE NEWSWIRE) — Huize Holding Limited, (“Huize”, the “Company” or “we”) (NASDAQ: HUIZ), a leading […]
Bilibili Inc. Prices Offering of Convertible Senior Notes
SHANGHAI, China, May 29, 2020 (GLOBE NEWSWIRE) — Bilibili Inc. (“Bilibili” or the “Company”) (NASDAQ: BILI), a leading online entertainment […]
Chi-Med Announces NDA Acceptance in China for Savolitinib in the Treatment of Non-Small Cell Lung Cancer with MET Exon 14 Skipping Mutations
— First NDA filing of savolitinib globally —— Chi-Med seeking first-in-class Chinese marketing authorization for a selective MET inhibitor —LONDON, May 29, 2020 (GLOBE [...]
Tiziana Life Sciences announces presentation of StemPrintER, a superior prognostic test as compared to Oncotype DX to predict breast cancer
StemPrintER Outperforms Oncotype DX in analysis with 800+ samples from ER+/HER2- postmenopausal breast cancer patientsSPARE Model is up to 40-50% […]
